[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591581":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":12,"collaborators":10,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":21,"acronym":10,"eligibilityCriteria":22,"healthyVolunteers":18,"sex":23,"minAge":24,"maxAge":10,"enrollmentInfo":25,"targetDuration":10,"studyType":28,"phases":10,"briefSummary":29,"conditions":30,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":10},{"fullName":5,"class":6},"Sir Run Run Shaw Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Experimental Group",null,"patients treated with anlotinib Hydrochloride combined with immunotherapy maintenance therapy following standard chemoimmunotherapy.",{"type":13,"investigatorFullName":14,"investigatorTitle":15,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Yong Fang","professor","100591581","a-retrospective-real-world-study-on-the-efficacy-and-safety-of-anlotinib-hydrochloride-combined-with-immunotherapy-maintenance-therapy-following-standard-chemoimmunotherapy-for-es-sclc-alter-l059-100591581",false,"NCT06982287","A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)","A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy as Maintenance Therapy Following First-Line Chemoimmunotherapy in Treatment-Naïve Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (ALTER-L059)","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older;\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (per the Veterans Administration Lung Study Group \\[VALG\\] staging criteria);\n3. Patients who previously received chemotherapy for limited-stage SCLC must have undergone curative-intent therapy (e.g., chemotherapy, radiotherapy, or chemoradiotherapy) and have a treatment-free interval of at least 6 months from the end of prior therapy (last chemotherapy cycle or radiotherapy) to the diagnosis of ES-SCLC;\n4. At least one measurable target lesion (per RECIST version 1.1 criteria);\n5. No disease progression after receiving 4-6 cycles of first-line chemoimmunotherapy induction therapy for ES-SCLC;\n6. ECOG performance status: 0-2;\n7. Life expectancy ≥3 months.\n\nExclusion Criteria:\n\n1. Patients with limited-stage SCLC who previously received chemotherapy and underwent curative-intent therapy (e.g., chemotherapy, radiotherapy, or chemoradiotherapy) but experienced disease recurrence within 6 months after completion of prior therapy;\n2. Patients with limited-stage SCLC who previously received immunotherapy agents (e.g., PD-1\u002FPD-L1 inhibitors) or anti-angiogenic agents (e.g., Anlotinib, Apatinib, Bevacizumab);\n3. Patients with extensive-stage small cell lung cancer (ES-SCLC) who developed disease progression during induction therapy with a standard chemoimmunotherapy regimen;\n4. Active autoimmune diseases requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose;\n5. Patients with coagulation dysfunction, defined as an International Normalized Ratio (INR) \\>1.5 or activated partial thromboplastin time (APTT) \\>1.5 × upper limit of normal (ULN), and\u002For those with a bleeding tendency;\n6. Patients deemed by the inves.","ALL","18 Years",{"count":26,"type":27},100,"ESTIMATED","OBSERVATIONAL","This retrospective real-world study aims to evaluate the efficacy and safety of anlotinib hydrochloride combined with immunotherapy as maintenance therapy following standard chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC).The study population consists of treatment-naïve ES-SCLC patients who did not progress after induction chemoimmunotherapy and subsequently received maintenance therapy with anlotinib plus immunotherapy. The primary objectives are progression-free survival (PFS)，overall survival (OS)\n\n, and safety.",[31],"Small Cell Lung Cancer Extensive Stage","NOT_YET_RECRUITING","2025-07-04",{"date":35,"type":36},"2025-07-08","ACTUAL",{"date":38,"type":27},"2025-08-01",{"date":40,"type":27},"2025-12-31",{"name":14,"class":6}]